Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rhabdomyosarcoma Immunotherapy
Research on rhabdomyosarcoma immunotherapy discussed by scientists at National Institutes of Health
August 20th, 2008
Investigators publish new data in the report 'A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.' According to recent research from the United States, "Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies. This study administered a novel immunotherapy regimen aimed at consolidating remission in these patients." "Fifty-two patients with translocation positive, recurrent, or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma underwent prechemotherapy cell harvest via apheresis for potential receipt of immunotherapy....
Source: Vaccine Weekly (2008-08-20)
|
